As 2024 draws to a close, we at Indica Labs would like to thank the customers and collaborators who helped fill 2024 with exciting discoveries, events, and partnerships. It is a great honor to have played a part in customers’ contributions to scientific fields ranging from immuno-oncology to infectious disease, immunology, neuroscience, and metabolism.
Looking Back: Reviewing 2024 at Indica Labs Read More »
With the HALO AP platforms and their dedicated Tumor Board functionalities, pathologists can enhance multidisciplinary communication and improve treatment planning.
10 October 2024 | Join us for this 1-hour webinar to learn about HALO AP platforms with regulatory clearances supporting diagnostic workflows in the US (FDA cleared HALO AP Dx) and in the EU and UK (CE-IVDR marked HALO AP®).
HALO AP® and HALO AP Dx: Pathologist-Centric Enterprise Digital Pathology Platforms Read More »
Albuquerque, NM – 2 July 2024 – Indica Labs today announces the expansion of their reseller network in the Asia Pacific (APAC) region.
Albuquerque, NM, and Hamamatsu City, Japan – 22 May, 2024 – Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform.
Albuquerque, NM – 8 May 2024 – Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis.
Indica Labs Receives First FDA Clearance for HALO AP Dx Digital Pathology Platform Read More »
13 June 2024 | Join us for this 1-hour webinar to see a live demonstration of HALO AP Dx, the 510k-cleared digital pathology platform from Indica Labs.
Introducing HALO AP Dx: An Enterprise Pathology Platform for Primary Diagnosis Read More »
